TB Europe Coalition among the 83
organisations and 106 individuals, signed an open letter, calls on J&J to publicly
commit to non-enforcement of the secondary patent on the fumarate salt
formulation and any other versions of bedaquiline and withdrawal of all pending
applications for the secondary patent at or before the United Nations High
Level Meeting on TB this September 22, 2023.
Please
share widely in your networks and on social media this open letter to J&J demanding the company take urgent
action necessary for equitable access to generic bedaquiline in all countries
with high burdens of TB, MDR-TB, and TB/HIV after the primary patent expires on
July 18, 2023
https://www.treatmentactiongroup.org/wp-content/uploads/2023/07/open_letter_urgent_action_necessary_equitable_access_to_bedaquiline.pdf
